In obese insulin-resistant adults with type 2 diabetes on high-dose insulin, adding liraglutide significantly reduced HbA1c at 6 months compared with insulin only.
In plain wordsIn adults with type 2 diabetes on high-dose insulin, adding liraglutide lowered HbA1c more than insulin alone.
- Peptide
- Liraglutide
- Outcome
- DecreaseHbA1c
- Study
n = 37
- Comparator
- Intensive insulin only
- Outcome group
- Glycemic control · Metabolic and weight
- Studied dose
- 0.6 mg per day, increased to 1.2 or 1.8 mg daily · subcutaneous · 6 monthsAs given in this study (human).
Source sentences
At 6 months, subjects receiving liraglutide plus insulin experienced statistically significant reductions in HbA1c, weight, insulin dose and glycaemic variability (GV) by continuous glucose monitor (CGM) compared with the control group receiving insulin only.
2 context sentences(design, population, supporting numbers)
Thirty-seven subjects with type 2 diabetes requiring >100 units of insulin daily administered either by continuous subcutaneous insulin infusion (CSII) or by multiple daily injections (MDIs) with or without metformin were randomized to receive either liraglutide plus insulin (LIRA) or intensive insulin only (controls).
Liraglutide was initiated at 0.6 mg subcutaneously (sq) per day and increased to either 1.2 or 1.8 mg daily in combination with intensive insulin therapy.